The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
- Resource Type
- Article
- Authors
- Saturno, G.; Lopes, F.; Niculescu-Duvaz, I.; Niculescu-Duvaz, D.; Zambon, A.; Davies, L.; Johnson, L.; Preece, N.; Lee, R.; Viros, A.; Holovanchuk, D.; Pedersen, M.; McLeary, R.; Lorigan, P.; Dhomen, N.; Fisher, C.; Banerji, U.; Dean, E.; Krebs, M.G.; Gore, M.; Larkin, J.; Marais, R.; Springer, C.
- Source
- In Annals of Oncology February 2021 32(2):269-278
- Subject
- Early drug development
- Language
- ISSN
- 0923-7534